# Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

> **NCT03263637** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 44 (actual)

## Conditions studied

- Relapsed or Refractory Haematological Malignancies Including
- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- High Risk Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia
- Richter's Syndrome
- B-cell Non-Hodgkin Lymphoma
- T-cell Non-Hodgkin Lymphoma
- Small Lymphocytic Lymphoma
- Multiple Myeloma

## Interventions

- **DRUG:** AZD4573

## Key facts

- **NCT ID:** NCT03263637
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-24
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263637, "Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03263637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*